^
FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
Cancer Discov - 3 weeks
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
Cancer Discov - 3 weeks
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
JAMA Oncol - 3 weeks
FGFR2-POC1B fusion
Cholangiocarcinoma
TAS 120
Sensitive: C4 – Case Studies
Cancer Discov - 3 weeks
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Cholangiocarcinoma
infigratinib
Sensitive: B - Late Trials
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive: B - Late Trials
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive: C1 - Off-label
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA1 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
NTRK2 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
FGFR2 translocation
Cholangiocarcinoma
pemigatinib
Sensitive: C2 – Inclusion Criteria
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TAS 120
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
Cholangiocarcinoma
dasatinib
Sensitive: C2 – Inclusion Criteria
IDH1 R132C
Cholangiocarcinoma
ivosidenib
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Cholangiocarcinoma
metformin
Sensitive: C2 – Inclusion Criteria
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Cholangiocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
DDR
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive: C3 – Early Trials
PD-L1 expression
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive: C3 – Early Trials
ARID1A mutation
Cholangiocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
FGFR2 fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
KRAS G12C
Cholangiocarcinoma
MRTX849
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD1 inhibitor + PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD-L1 inhibitor
Sensitive: C3 – Early Trials
POLE mutation
Cholangiocarcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
MET-H
Cholangiocarcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
TIMP1-L
Cholangiocarcinoma
cabozantinib tablet
Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
FGFR2-SORBS1 fusion
Cholangiocarcinoma
TAS 120
Resistant: C3 – Early Trials
FGFR3 fusion
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 fusion
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
FGFR1 fusion
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
TP53 mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
TP53 mutation + FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
PBRM1 mutation + FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
PIK3CA mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
PIK3CB mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
PIK3R1 mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
BAP1 mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
BAP1 mutation + FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
IDH1 mutation + FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
IDH1 mutation + FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion
Cholangiocarcinoma
infigratinib + PD 0173074
Sensitive: C3 – Early Trials
FGFR2-AHCYL1 fusion
Cholangiocarcinoma
infigratinib + PD 0173074
Sensitive: C3 – Early Trials
FGFR2 Y376C
Cholangiocarcinoma
ABSK-091
Sensitive: C3 – Early Trials
BAP1 mutation
Cholangiocarcinoma
cisplatin + gemcitabine
Resistant: C3 – Early Trials
MALT1 expression
Cholangiocarcinoma
regorafenib
Sensitive: C3 – Early Trials
EFNB2 positive
Cholangiocarcinoma
sEphB4-HSA
Sensitive: C3 – Early Trials
EFNB2 negative
Cholangiocarcinoma
sEphB4-HSA
Sensitive: C3 – Early Trials
HER-2 amplification
Cholangiocarcinoma
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
FGFR2 C382R
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
DCK positive
Cholangiocarcinoma
gemcitabine
Sensitive: C3 – Early Trials
FGFR2-KIAA1217 fusion
Cholangiocarcinoma
ARQ 087
Sensitive: C3 – Early Trials
FGFR2-KIAA1217 fusion
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
FGFR2 inhibitor
Resistant: C3 – Early Trials
LMNA-NTRK1 fusion + NTRK1 G595R
Cholangiocarcinoma
TPX-0005
Sensitive: C3 – Early Trials
dMMR/MSI-H + TMB-L
Cholangiocarcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
PTEN mutation + MSI-H/dMMR
Cholangiocarcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
FGFR2 F276C
Cholangiocarcinoma
pemigatinib
Sensitive: C3 – Early Trials
FGFR2 translocation
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
FGFR2 mutation
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
HER-2 mutation
Cholangiocarcinoma
trastuzumab
Resistant: C4 – Case Studies
FGFR2-NRAP fusion
Cholangiocarcinoma
TAS 120
Resistant: C4 – Case Studies
MSI-H/dMMR + PD-1 expression + CD8 positive
Cholangiocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
FGFR2-CLIP1 fusion
Cholangiocarcinoma
pemigatinib
Resistant: C4 – Case Studies
FGFR2-OPTN fusion
Cholangiocarcinoma
infigratinib
Resistant: C4 – Case Studies
FGFR2-BICC1 fusion
Cholangiocarcinoma
infigratinib
Resistant: C4 – Case Studies
VHL mutation
Cholangiocarcinoma
sunitinib
Sensitive: C4 – Case Studies
PD-L1 overexpression
Cholangiocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
EHBP1‐MET fusion
Cholangiocarcinoma
crizotinib
Sensitive: C4 – Case Studies
MSI-H/dMMR + PD-L1 expression
Cholangiocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
BRCA1 mutation + PD-L1 expression
Cholangiocarcinoma
pembrolizumab + olaparib
Sensitive: C4 – Case Studies
BRAF mutation
Cholangiocarcinoma
LTT462
Sensitive: C4 – Case Studies
HER-2 amplification
Cholangiocarcinoma
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: C4 – Case Studies